Heart failure with preserved ejection fraction (HFpEF) can prove a complex problem for clinicians — its prevalence is increasing, it mimics many other conditions, and it can have a devastating impact ...
ISSAQUAH, Wash.--(BUSINESS WIRE)--BaroPace Inc. announces its Phase I first-in-human trial of PressurePace TM, its patent-pending pacemaker control algorithm for the treatment of heart failure with ...
Please provide your email address to receive an email when new articles are posted on . A new expert consensus decision pathway stresses proper diagnosis and treatment of HF with preserved ejection ...
Patients with heart failure with preserved ejection fraction (HFpEF) represent approximately 50% of all HF cases. Whereas several proven medical therapies are available for HF with reduced ejection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback